Resource Logo
Gay Men's Health Crisis

DRUG WATCH: Japanese Company Invests in Vertex




 

GMHC Treatment Issues 1993 May 1; 7(5): 11

Kissei, a Japanese drug company, paid $20 million for Asian marketing rights to Vertex's HIV protease inhibitors. Vertex has several protease compounds in preclinical development. Vertex claims its protease compounds are more potent than Abbott's and more bioavailable than Roche's.

Copyright (c) 1993 - GMHC Treatment Issues. Noncommercial reproduction encouraged. Distributed by AEGIS, your online gateway to a world of people, knowledge, and resources. Direct Dial: v.34+: 714.248.2836; v.120/ISDN: 714.248.0433 Internet: telnet:aegis.com www: www.aegis.com



 


Copyright © 1993 -Gay Men's Health Crisis, Publisher. All rights reserved to Gay Men's Health Crisis (GMHC) Treatment Issues. Reproduced with permission. Treatment Issues is published twelve times yearly by GMHC, INC. Noncommercial reproduction is encouraged. Subscription lists are kept confidential. GMHC Treatment Issues, The Tisch Building, 119 West 24th Street, New York, NY 10011 Email GMHC. Visit GMHC

Information in this article was accurate in May 1, 1993. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.